<<Back
Chembio Awarded Grant From the Paul G. Allen Ebola Program to Develop a Multiplex Point-of-Care Test for Febrile Illnesses
Febrile illnesses present with a high-grade fever and can have high morbidity and mortality when not treated appropriately. In many parts of the world, these diseases are commonly misdiagnosed, resulting in a delay of treatment or failure to properly treat the underlying infection. Misdiagnosis may be due to the fact that these diseases have similar symptoms that are difficult to identify.
Currently available POC diagnostics lack the ability to test for multiple diseases simultaneously. Further, existing POC diagnostics may lack the sensitivity and specificity required to detect infected but asymptomatic patients - information that is critical for preventing the spread of disease. Through this grant, it is the goal of the Paul G. Allen Ebola Program to develop a simple, cost-effective, point-of-care diagnostic capable of testing for multiple diseases simultaneously, to ensure that patients receive the appropriate treatment, and healthcare workers offer optimal care to communities through the accurate diagnosis of febrile illness.
Chembio's DPP® Fever Panel Assay will be designed to include a quality control test band and seven tests bands with specific antibodies to detect different pathogens, including multiple serotypes of the same pathogen: Malaria PAN-PLDH antigen (Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale), Malaria Falciparum HRP2 antigen, Ebola Virus PAN (
In launching this new program, Chembio affirms its commitment to the development of new and much-needed POC tests for life threatening fever diseases. Our patented DPP
® technology platform and our recent progress in this area uniquely qualify us for this important project. Chembio is currently working with the
For more information on today's announcement, please visit:
www.PaulAllen.com/News/News-Articles/Ebola-RFP-Announcement
www.PaulAllen.com/Ebola-Program
About
Chembio has developed a patented point-of-care (POC) test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.
Headquartered in
Forward-Looking Statements
Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance
may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the
CONTACTS:Source:Chembio Diagnostics Susan Norcott (631) 924-1135, ext. 125 snorcott@chembio.comVida Strategic Partners Stephanie C. Diaz (investor relations) (415) 675-7401 sdiaz@vidasp.comTim Brons (media) (415) 675-7401 tbrons@vidasp.com
News Provided by Acquire Media